Cargando…

Risk factors for thromboembolism during first-line treatment of patients with unresectable advanced or recurrent colorectal cancer: a retrospective short study

BACKGROUND: While cancer is a risk factor for developing thromboembolism, so is the use of molecularly targeted therapies. This study aimed to determine whether thromboembolism incidence differed between vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takada, Ryo, Fujiwara, Miki, Maki, Masatoshi, Takahashi, Yoko, Tamura, Koji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316546/ https://www.ncbi.nlm.nih.gov/pubmed/37394446 http://dx.doi.org/10.1186/s40780-023-00291-0

Ejemplares similares

Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease
por: Aparicio, Jorge, et al.
Publicado: (2020)

Genomic temporal heterogeneity of circulating tumour DNA in unresectable metastatic colorectal cancer under first-line treatment
por: Wang, Feng, et al.
Publicado: (2022)

Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel
por: Yamai, Takuo, et al.
Publicado: (2022)

Phase I study of cisplatin analogue nedaplatin (254-S) and paclitaxel in patients with unresectable squamous cell carcinoma
por: Sekine, I, et al.
Publicado: (2004)

Therapeutic response to a novel enzyme-targeting radiosensitization treatment (Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas) in patients with recurrent breast cancer
por: AOYAMA, NOBUTAKA, et al.
Publicado: (2016)

Image-guidedcryoablation in unresectable or recurrent advanced colorectal cancer: a retrospective study
por: Wang, Guang-Zhi, et al.
Publicado: (2019)

Immune checkpoint inhibitor therapy and elevated levels of C-reactive protein associated with COVID-19 aggravation in patients with lung cancer
por: Maki, Masatoshi, et al.
Publicado: (2022)

Current Status of Angiogenesis Inhibitors as Second-Line Treatment for Unresectable Colorectal Cancer
por: Otsu, Satoshi, et al.
Publicado: (2023)

Unresectable Advanced Gastric Cancer with Skin Invasion followed by Total Gastrectomy after Second-Line Chemotherapy
por: Maki, Hidenori, et al.
Publicado: (2019)

Role of Nivolumab in the Management of First-Line Unresectable Advanced or Recurrent Gastric Cancer in Combination with Chemotherapy: Lessons from the Japanese Experience
por: Kubota, Yohei, et al.
Publicado: (2022)

Short‐term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone
por: Zhang, Run‐zi, et al.
Publicado: (2019)

Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer
por: Elshenawy, Mahmoud A., et al.
Publicado: (2020)

First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study
por: Van Cutsem, E., et al.
Publicado: (2022)

Analysis of Response Evaluation Criteria in Solid Tumors reduction ratio of primary chemotherapy in unresectable advanced or recurrent colorectal cancer
por: Kawagoe, Shiho, et al.
Publicado: (2019)

Unresectable metastatic colorectal cancer in fit patients – a practical algorithm of treatment sequencing from the Brazilian Group of Gastrointestinal Tumours (GTG)
por: Peixoto, Renata D’Alpino, et al.
Publicado: (2023)

CT-guided cryoablation for unresectable pelvic recurrent colorectal cancer: a retrospective study
por: Wang, Ying, et al.
Publicado: (2019)

A short line segment squirms along a zigzag line
por: Ito, Hiroyuki, et al.
Publicado: (2013)

Balloon Pulmonary Angioplasty for Recurrent Lesions Six Years Following Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension
por: Tamura, Hiroto, et al.
Publicado: (2023)

Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial
por: Qin, Shukui, et al.
Publicado: (2023)

Venous thromboembolism in women
por: Peclat, Ana Paula Rolim Maia, et al.
Publicado: (2023)

Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma
por: Takada, Hitomi, et al.
Publicado: (2019)

Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer
por: Hirose, Toshiharu, et al.
Publicado: (2023)

Dose-intense capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multi-centre phase II study
por: Jackson, Christopher GCA, et al.
Publicado: (2014)

Application of Tumor Burden Score for predicting conversion outcome in patients with initially unresectable colorectal liver metastases after first-line systemic therapy
por: Peng, Jianhong, et al.
Publicado: (2021)

A Case of Unresectable Combined Hepatocellular-Cholangiocarcinoma Successfully Treated with Lenvatinib
por: Osuga, Takahiro, et al.
Publicado: (2022)

Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib
por: Hiraoka, Atsushi, et al.
Publicado: (2022)

Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2022)

Antiplatelet Therapy for Prevention of Thromboembolic Complications Associated with Coil Embolization of Unruptured Cerebral Aneurysms
por: Matsumoto, Yasushi, et al.
Publicado: (2012)

Circumstances of provoked recurrent venous thromboembolism: the Austrian study on recurrent venous thromboembolism
por: Puhr, Hannah C., et al.
Publicado: (2019)

A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer
por: Lee, J-L, et al.
Publicado: (2008)

Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients
por: Sugimoto, Shinichi, et al.
Publicado: (2009)

Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
por: Melisi, Davide, et al.
Publicado: (2018)

A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma
por: Drysdale, Erik, et al.
Publicado: (2019)

Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
por: Wang, Shijie, et al.
Publicado: (2022)

First-line systemic treatment strategies for unresectable hepatocellular carcinoma: A cost-effectiveness analysis
por: wang, Liting, et al.
Publicado: (2023)

First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis
por: Yang, Liu, et al.
Publicado: (2023)

A Phase II Clinical Study of mFOLFOX6 Plus Bevacizumab as First-line Therapy for Japanese Advanced/Recurrent Colorectal Cancer Patients
por: Nishina, Tomohiro, et al.
Publicado: (2013)

PROTOCOL FOR LIVER TRANSPLANTATION IN UNRESECTABLE COLORECTAL METASTASIS
por: ERNANI, Lucas, et al.
Publicado: (2022)

Impact of skeletal muscle mass in patients with unresectable gastric cancer who received palliative first-line chemotherapy based on 5-fluorouracil
por: Matsunaga, Tomoyuki, et al.
Publicado: (2021)

Atrial Fibrillation and Cryptogenic Thromboembolic Events
por: Henz, Benhur Davi, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qth2evn4aifq4enbeiah8qc9iq